All In MedTech

Device Trial Radar · NCT03973866

Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)

Alfapump® System in the Treatment of Refractory or Recurrent Ascites: a Multicenter Single Arm Within Subject Crossover Design Pivotal Study (the POSEIDON Study)

Last checked: Nov 19, 2026Latest source record: Dec 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

110

Actual

Start

Sep 16, 2019

Primary completion

Mar 30, 2024

Study completion Jun 30, 2024

Sponsor

Lead sponsor
Sequana Medical N.V.Not on our public-company list
Sponsor type
Industry
First posted
Jun 4, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The POSEIDON study is a multi-center, prospective, single arm, crossover pivotal study enrolling up to 70 pivotal cohort patients and up to 45 additional Roll-in patients with refractory or recurrent ascites at up to 20 sites. Pivotal cohort patients will undergo a 3-month pre-implant observation phase after enrollment, followed by implantation of the alfapump and 24 months of post-implant follow up. An analysis will be conducted to support an application for device approval when a minimum of 40 treated pivotal cohort patients are through 6 months.

Conditions

  • Ascites

Interventions

  • AlfapumpDevice

    Implantation of alfapump

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Per-patient ratio of post-implant to pre-implant with respect to average monthly number of therapeutic paracentesisTime frame: Comparing data from the post-implant 3-month observation period to data from the pre-implant 3-month observation period:
  2. Proportion of patients with at least 50% reduction in number of therapeutic paracenteses from the pre-observation period to post-observation periodTime frame: Comparing data from the post-implant 3-month observation period to data from the pre-implant 3-month observation period
  3. Combined rate of open surgical reintervention due to pump system related adverse event or to restore pump functionality, pump explant due to pump system related adverse event, or pump system related deathTime frame: from time of pump implant through 6 months post-implant

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic (Arizona)

    Phoenix, Arizona

  • Cedars-Sinai Comprehensive Transplant Center

    Los Angeles, California

  • University of Massachusetts Memorial Medical Center

    Worcester, Massachusetts

12 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.